Welcome to our dedicated page for Atricure news (Ticker: ATRC), a resource for investors and traders seeking the latest updates and insights on Atricure stock.
AtriCure, Inc. (symbol: ATRC) is a leading provider of cutting-edge medical technologies aimed at treating atrial fibrillation (Afib) and related conditions. With over 33 million people affected by Afib globally, AtriCure stands at the forefront of developing innovative solutions to combat this prevalent health issue. Electrophysiologists and cardiothoracic surgeons around the world rely on AtriCure's products to reduce complications associated with Afib.
The company's flagship product, the Isolator® Synergy™ Ablation System, is notably the first and only device approved by the FDA for the treatment of persistent Afib. Additionally, the AtriClip Left Atrial Appendage Exclusion System holds the title of the most widely sold LAA management device globally, with over 100,000 units implanted to date.
AtriCure's diverse product line includes solutions for Cryoablation, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, among others. They also offer a range of minimally invasive ablation devices and access tools catering to the increasing demand for less invasive cardiac and thoracic surgeries. Their products are distributed to medical centers through a combination of a direct sales force and a network of distributors.
Geographically, the majority of AtriCure's revenue is generated from the United States. The company continues to expand its impact through ongoing projects, research, and partnerships aimed at improving patient outcomes and advancing the field of cardiac surgery.
For more detailed information about AtriCure's latest developments, visit their official website at AtriCure.com or follow them on Twitter @AtriCure.
AtriCure, Inc. (NASDAQ: ATRC), known for its innovative therapies for atrial fibrillation (Afib) and related conditions, announced an upcoming investor education webcast in collaboration with Canaccord Genuity, focusing on Cryo Nerve Block Therapy. This event is scheduled for May 16, 2023, at 12:30 PM Eastern Time, featuring a Q&A session with management and a key opinion leader.
Additionally, AtriCure will present at the 2023 Bank of America Health Care Conference on May 10, 2023, at 11:00 AM Eastern Time. Both events aim to enhance investor understanding of AtriCure's cutting-edge technologies, including the Isolator® Synergy™ Ablation System, which is FDA-approved for persistent Afib treatment.
Interested participants can access live and archived webcasts through the Investors section of AtriCure's website.
AtriCure, Inc. (NASDAQ: ATRC), a leader in surgical treatments for atrial fibrillation (Afib), announced its first quarter 2023 financial results will be released on May 2, 2023. The company will host an audio webcast at 4:30 p.m. Eastern Time on the same day to discuss these results. Interested participants can register here. AtriCure focuses on innovative technologies for Afib treatment, with products like the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System, addressing a condition affecting over 37 million people worldwide.
AtriCure, a leader in innovative surgical treatments for atrial fibrillation (Afib), announced its participation in the 22nd Annual Needham Virtual Healthcare Conference. The company’s management will conduct a fireside chat on April 17, 2023, at 1:30 PM EST. Interested parties can access a live audio webcast in the ‘Investors’ section on AtriCure's website. AtriCure focuses on the development of technologies for Afib treatment and LAA management, with over 37 million individuals affected by Afib globally. The firm’s devices, including the Isolator® Synergy™ Ablation System and the AtriClip® LAA Exclusion System, are widely used by healthcare professionals.